- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 376123, 12 pages
Emodin and Aloe-Emodin Suppress Breast Cancer Cell Proliferation through ERα Inhibition
1Department of Life Sciences, National Chung Hsing University, Taichung 40227, Taiwan
2Department of Health and Nutrition Biotechnology, Asia University, Taichung 41354, Taiwan
3Graduate Institute of Basic Medical Science, China Medical University, Taichung 40402, Taiwan
4Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
5Department of Surgery, Chang Bing Show Chwan Memorial Hospital, Changhua 50544, Taiwan
6Department of Surgery, Tungs’ Taichung MetroHarbor Hospital, Taichung 43304, Taiwan
7Department of Nuclear Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan
8Department of Agricultural Biotechnology Center, National Chung Hsing University, Taichung 40227, Taiwan
9Graduate Institute of Rehabilitation Science, China Medical University, Taichung 40402, Taiwan
Received 25 April 2013; Accepted 6 June 2013
Academic Editor: Gautam Sethi
Copyright © 2013 Pao-Hsuan Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Q. Huang, G. Lu, H.-M. Shen, M. C. M. Chung, and N. O. Choon, “Anti-cancer properties of anthraquinones from rhubarb,” Medicinal Research Reviews, vol. 27, no. 5, pp. 609–630, 2007.
- A. Dutta, S. Bandyopadhyay, C. Mandal, and M. Chatterjee, “Aloe vera leaf exudate induces a caspase-independent cell death in Leishmania donovani promastigotes,” Journal of Medical Microbiology, vol. 56, no. 5, pp. 629–636, 2007.
- H.-H. Wang and J.-G. Chung, “Emodin-induced inhibition of growth and DNA damage in the Helicobacter pylori,” Current Microbiology, vol. 35, no. 5, pp. 262–266, 1997.
- C.-H. Chang, C.-C. Lin, J.-J. Yang, T. Namba, and M. Hattori, “Anti-inflammatory effects of emodin from Ventilago leiocarpa,” American Journal of Chinese Medicine, vol. 24, no. 2, pp. 139–142, 1996.
- T.-L. Cha, L. Qiu, C.-T. Chen, Y. Wen, and M.-C. Hung, “Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth,” Cancer Research, vol. 65, no. 6, pp. 2287–2295, 2005.
- H. Matsuda, H. Shimoda, T. Morikawa, and M. Yoshikawa, “Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity,” Bioorganic and Medicinal Chemistry Letters, vol. 11, no. 14, pp. 1839–1842, 2001.
- S. C. Kang, C. M. Lee, E. S. Choung et al., “Anti-proliferative effects of estrogen receptor-modulating compounds isolated from Rheum palmatum,” Archives of Pharmacal Research, vol. 31, no. 6, pp. 722–726, 2008.
- F. Acconcia and R. Kumar, “Signaling regulation of genomic and nongenomic functions of estrogen receptors,” Cancer Letters, vol. 238, no. 1, pp. 1–14, 2006.
- S. Ali and R. C. Coombes, “Endocrine-responsive breast cancer and strategies for combating resistance,” Nature Reviews Cancer, vol. 2, no. 2, pp. 101–112, 2002.
- C. K. Osborne, “Tamoxifen in the treatment of breast cancer,” The New England Journal of Medicine, vol. 339, no. 22, pp. 1609–1618, 1998.
- G. A. Colditz, S. E. Hankinson, D. J. Hunter et al., “The use of estrogens and progestins and the risk of breast cancer in postmenopausal women,” The New England Journal of Medicine, vol. 332, no. 24, pp. 1589–1593, 1995.
- H. Adlercreutz and W. Mazur, “Phyto-oestrogens and Western diseases,” Annals of Medicine, vol. 29, no. 2, pp. 95–120, 1997.
- M. C. Chen, C. Y. Huang, S. L. Hsu et al., “Retinoic acid Induces apoptosis of prostate cancer DU145 cells through Cdk5 overactivation,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 580736, 11 pages, 2012.
- H. Lin and P. S. Wang, “Inhibitory effects of digoxin on testosterone production in rat Leydig cells,” Adaptive Medicine, vol. 4, pp. 165–172, 2012.
- H. Lin, T.-Y. Lin, and J.-L. Juang, “Abl deregulates Cdk5 kinase activity and subcellular localization in Drosophila neurodegeneration,” Cell Death and Differentiation, vol. 14, no. 3, pp. 607–615, 2007.
- H. Lin, M.-C. Chen, C.-Y. Chiu, Y.-M. Song, and S.-Y. Lin, “Cdk5 regulates STAT3 activation and cell proliferation in medullary thyroid carcinoma cells,” Journal of Biological Chemistry, vol. 282, no. 5, pp. 2776–2784, 2007.
- H. Lin, M.-C. Chen, and C.-T. Ku, “Cyclin-dependent kinase 5 regulates steroidogenic acute regulatory protein and androgen production in mouse Leydig cells,” Endocrinology, vol. 150, no. 1, pp. 396–403, 2009.
- H. Lin, J.-L. Juang, and P. S. Wang, “Involvement of Cdk5/p25 in digoxin-triggered prostate-cancer cell apoptosis,” Journal of Biological Chemistry, vol. 279, no. 28, pp. 29302–29307, 2004.
- F.-N. Hsu, M.-C. Chen, M.-C. Chiang et al., “Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5,” Journal of Biological Chemistry, vol. 286, no. 38, pp. 33141–33149, 2011.
- M.-C. Chen, S.-W. Wang, S.-F. Kan, S.-C. Tsai, Y.-C. Wu, and P. S. Wang, “Stimulatory effects of propylthiouracil on pregnenolone production through upregulation of steroidogenic acute regulatory protein expression in rat granulosa cells,” Toxicological Sciences, vol. 118, no. 2, Article ID kfq302, pp. 667–674, 2010.
- M. Dalvai and K. Bystricky, “Cell cycle and anti-estrogen effects synergize to regulate cell proliferation and er target gene expression,” PLoS One, vol. 5, no. 6, Article ID e11011, 2010.
- N. Heldring, A. Pike, S. Andersson et al., “Estrogen receptors: how do they signal and what are their targets,” Physiological Reviews, vol. 87, no. 3, pp. 905–931, 2007.
- Y. Miyoshi, K. Murase, M. Saito, M. Imamura, and K. Oh, “Mechanisms of estrogen receptor-α upregulation in breast cancers,” Medical Molecular Morphology, vol. 43, no. 4, pp. 193–196, 2010.
- M. Fan, A. Park, and K. P. Nephew, “CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-α,” Molecular Endocrinology, vol. 19, no. 12, pp. 2901–2914, 2005.
- R. A. Walker, “Oestrogen receptor and its potential role in breast cancer development,” The Journal of Pathology, vol. 188, no. 3, pp. 229–230, 1999.
- D. J. Mangelsdorf, C. Thummel, M. Beato et al., “The nuclear receptor super-family: the second decade,” Cell, vol. 83, no. 6, pp. 835–839, 1995.
- J. M. Hall, J. F. Couse, and K. S. Korach, “The multifaceted mechanisms of estradiol and estrogen receptor signaling,” Journal of Biological Chemistry, vol. 276, no. 40, pp. 36869–36872, 2001.
- V. C. Jordan, “Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer,” British Journal of Pharmacology, vol. 147, no. 1, pp. S269–S276, 2006.
- A. L. Murkies, G. Wilcox, and S. R. Davis, “Phytoestrogens,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 2, pp. 297–303, 1998.
- E. Nikander, A. Kilkkinen, M. Metsä-Heikkilä et al., “A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients,” Obstetrics and Gynecology, vol. 101, no. 6, pp. 1213–1220, 2003.
- Y. Imai, S. Tsukahara, S. Asada, and Y. Sugimoto, “Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance,” Cancer Research, vol. 64, no. 12, pp. 4346–4352, 2004.
- H. Jayasuriya, N. M. Koonchanok, R. L. Geahlen, J. L. McLaughlin, and C.-J. Chang, “Emodin, a protein tyrosine kinase inhibitor from Polygonum cuspidatum,” Journal of Natural Products, vol. 55, no. 5, pp. 696–698, 1992.
- L. Zhang, C.-J. Chang, S. S. Bacus, and M.-C. Hung, “Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin,” Cancer Research, vol. 55, no. 17, pp. 3890–3896, 1995.
- L. Zhang and M.-C. Hung, “Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin,” Oncogene, vol. 12, no. 3, pp. 571–576, 1996.
- T.-H. Chou and C.-H. Liang, “The molecular effects of Aloe-Emodin (AE)/liposome-AE on human nonmelanoma skin cancer cells and skin permeation,” Chemical Research in Toxicology, vol. 22, no. 12, pp. 2017–2028, 2009.
- Y.-Y. Yan, L.-S. Zheng, X. Zhang et al., “Blockade of Her2/neu binding to Hsp90 by emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu,” Molecular Pharmaceutics, vol. 8, no. 5, pp. 1687–1697, 2011.
- Y. Murakami, S. Matsufuji, T. Kameji et al., “Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination,” Nature, vol. 360, no. 6404, pp. 597–599, 1992.
- G. Asher and Y. Shaul, “p53 proteasomal degradation: poly-ubiquitination is not the whole story,” Cell Cycle, vol. 4, no. 8, pp. 1015–1018, 2005.
- S. Kocanova, M. Mazaheri, S. Caze-Subra, and K. Bystricky, “Ligands specify estrogen receptor alpha nuclear localization and degradation,” BMC Cell Biology, vol. 11, article 98, 2010.